Menu Search
Equities

Imunon Inc

IMNN:NAQ

Imunon Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.03
  • Today's Change-0.04 / -3.74%
  • Shares traded508.17k
  • 1 Year change-5.50%
  • Beta2.1301
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Imunon Inc had revenues fall -100.00% from 500.00k to 0.00, though the company grew net income from a loss of 35.90m to a smaller loss of 19.51m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-94.15%
Return on equity-143.19%
Return on investment-132.90%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Imunon Inc fell by 11.65m. However, Cash Flow from Investing totalled 11.01m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 19.02m for operations while cash used for financing totalled 3.64m.
Cash flow per share-1.90
Price/Cash flow per share--
Book value per share0.398
Tangible book value per share0.398
More ▼

Balance sheet in USDView more

Imunon Inc uses little or no debt in its capital structure.
Current ratio1.51
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.